NCT01902173 - Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 8, 2013

Primary Completion Date

May 16, 2018

Study Completion Date

December 23, 2023

Conditions

Hematopoietic and Lymphoid Cell NeoplasmLocally Advanced Malignant Solid NeoplasmLocally Advanced MelanomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaStage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Unresectable Malignant Solid NeoplasmUnresectable Melanoma

Interventions

PROCEDURE

Biopsy

Undergo a biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo a CT scan

DRUG

Dabrafenib Mesylate

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Trametinib Dimethyl Sulfoxide

Given PO

DRUG

Uprosertib

Given PO

Trial Locations (16)

43210

Ohio State University Comprehensive Cancer Center, Columbus

44195

Cleveland Clinic Foundation, Cleveland

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

80045

UCHealth University of Colorado Hospital, Aurora

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

94115

California Pacific Medical Center-Pacific Campus, San Francisco

UCSF Medical Center-Mount Zion, San Francisco

97015

Clackamas Radiation Oncology Center, Clackamas

97045

Providence Willamette Falls Medical Center, Oregon City

97132

Providence Newberg Medical Center, Newberg

97213

Providence Portland Medical Center, Portland

97222

Providence Milwaukie Hospital, Milwaukie

97225

Providence Saint Vincent Medical Center, Portland

97239

Oregon Health and Science University, Portland

98664

PeaceHealth Southwest Medical Center, Vancouver